Table 1.

Nonprocedural clinically significant bleedings (CSBs) during follow-up per patient.

No.	Post-LAAC CSB Site	Type	Time (Days)	APT	HAS-BLED	Pre-LAAC Bleeding Site	History of Comorbidities Associated with the Pre-LAAC Bleeding Site
1	GI	mCRB	233	single	2	intracranial	-
2	GI	mCRB	10	dual	1	GI	Crohn’s disease, S/P colon resection
3	GI	mCRB	18	dual	3	GI	diverticulosis and polyps in the colon, hemorrhoid disease, S/P chronic gastritis
4	epistaxis	nmCRB	140	none	3	epistaxis	-
5	epistaxis	mCRB	76	dual	1	epistaxis	HHT
6	GI	mCRB	76	dual	2	GI	diverticulosis, S/P polypectomy
7	GI	nmCRB	107	single	1	GI	S/P endoscopic resection of colorectal adenocarcinoma
8	GI	nmCRB	48	dual	1	GI	ulcerative colitis, chronic gastritis
9	epistaxis	mCRB	4	dual	1	epistaxis	HHT
10	GI	nmCRB	10	single	5	GI	gastric ulcer
11	GI	mCRB	46	dual	4	GI	gastric angiodysplasia, S/P argon plasma coagulation
12	genitourinary	nmCRB	16	dual	2	genitourinary	-
13/ 14	genitourinary	nmCRB	60/72	dual/ single	3	genitourinary	-
15	GI	mCRB (fatal)	323	none	2	GI	portal hypertension, alcoholic liver cirrhosis, peptic ulcer disease

APT = antiplatelet therapy during the event; CSB = clinically significant bleeding; GI = gastrointestinal bleeding; HHT = hereditary hemorrhagic telangiectasia; LAAC = left atrial appendage closure; mCRB = major clinically relevant bleeding; nmCRB = non-major clinically relevant bleeding, S/P = status post.